Topical 5-fluorouracil with photodynamic therapy as good as excision in Bowen's disease

Written By :  Dr. Shravani Dali
Medically Reviewed By :  Dr. Kamal Kant Kohli
Published On 2023-09-27 14:30 GMT   |   Update On 2023-09-27 14:30 GMT

Topical 5% 5-fluorouracil with photodynamic therapy as good as excision in Bowen's disease suggests a new study published in the Journal of the American Academy of Dermatology.Randomized controlled trials comparing the effectiveness of 5-fluorouracil cream, methylaminolevulinate photodynamic therapy (MAL-PDT) and surgical excision in patients with Bowen's disease are lacking. background...

Login or Register to read the full article

Topical 5% 5-fluorouracil with photodynamic therapy as good as excision in Bowen's disease suggests a new study published in the Journal of the American Academy of Dermatology.

Randomized controlled trials comparing the effectiveness of 5-fluorouracil cream, methylaminolevulinate photodynamic therapy (MAL-PDT) and surgical excision in patients with Bowen's disease are lacking. background METHODS: In this multicenter non-inferiority trial, patients with a histologically proven Bowen's disease of 4-40mm were randomly assigned to excision with 5mm margin, 5% 5-fluorouracil cream twice daily for four weeks, or two sessions of MAL-PDT with one week interval. The primary outcome was the proportion of patients with sustained clearance at 12 months after treatment. A non-inferiority margin of 22% was used.

Results:

Between May 2019 and January 2021, 250 patients were randomized. The proportion of patients with sustained clearance was 97.4% (75/77) after excision, 85.7% (66/77) after 5-fluorouracil and 82.1% (64/78) after MAL-PDT. Absolute differences were -11.7% (95% CI -18.9 to -4.5; P=0.0049) for 5-fluorouracil versus excision and -15.4% (95% CI -23.1 to -7.6; P=0.00078) for MAL-PDT versus excision. Both non-invasive treatments significantly more often led to good or excellent cosmetic outcome.

Based on our predefined non-inferiority margin of 22%, 5-fluorourcail is non-inferior to excision and associated with better cosmetic outcome. For MAL-PDT non-inferiority to excision cannot be concluded. Therefore, 5-fluorouracil should be preferred over excision and MAL-PDT in treatment of Bowen's disease.

Reference:

Ahmady S, Nelemans PJ, Kelleners-Smeets NWJ, Arits AHMM, de Rooij MJM, Kessels JPHM, Essers BAB, Mosterd K. Surgical excision versus topical 5% 5-fluorouracil and photodynamic therapy in treatment of Bowen's disease: a multicenter randomized controlled trial. J Am Acad Dermatol. 2023 Sep 2:S0190-9622(23)02662-2. doi: 10.1016/j.jaad.2023.08.076. Epub ahead of print. PMID: 37666424.

Keywords:

Topical, 5% 5-fluorouracil, photodynamic, therapy, as, good, excision, Bowen's disease, Ahmady S, Nelemans PJ, Kelleners-Smeets NWJ, Arits AHMM, de Rooij MJM, Kessels JPHM, Essers BAB, Mosterd K, Bowen’s disease; Squamous cell carcinoma; clinical research; drug response; fluorouracil; general dermatology; medical dermatology; oncology; photodynamic Therapy; skin cancer; surgery; therapy.

Tags:    
Article Source : Journal of the American Academy of Dermatology

Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News